Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Bi-Frequency Symmetry Difference EIT - Feasibility and Limitations of Application to Stroke Diagnosis.

McDermott BJ, Ohalloran M, Avery J, Porter E.

IEEE J Biomed Health Inform. 2019 Dec 19. doi: 10.1109/JBHI.2019.2960862. [Epub ahead of print]

PMID:
31869810
2.

Signalling mechanisms underlying doxorubicin and Nox2 NADPH oxidase-induced cardiomyopathy: involvement of mitofusin-2.

McLaughlin D, Zhao Y, O'Neill KM, Edgar KS, Dunne PD, Kearney AM, Grieve DJ, McDermott BJ.

Br J Pharmacol. 2017 Nov;174(21):3677-3695. doi: 10.1111/bph.13773. Epub 2017 Apr 22.

3.

Metabolically-inactive glucagon-like peptide-1(9-36)amide confers selective protective actions against post-myocardial infarction remodelling.

Robinson E, Tate M, Lockhart S, McPeake C, O'Neill KM, Edgar KS, Calderwood D, Green BD, McDermott BJ, Grieve DJ.

Cardiovasc Diabetol. 2016 Apr 14;15:65. doi: 10.1186/s12933-016-0386-5.

4.

Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages.

Tate M, Robinson E, Green BD, McDermott BJ, Grieve DJ.

Basic Res Cardiol. 2016 Jan;111(1):1. doi: 10.1007/s00395-015-0518-1. Epub 2015 Nov 23.

5.

Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix.

Robinson E, Cassidy RS, Tate M, Zhao Y, Lockhart S, Calderwood D, Church R, McGahon MK, Brazil DP, McDermott BJ, Green BD, Grieve DJ.

Basic Res Cardiol. 2015 Mar;110(2):20. doi: 10.1007/s00395-015-0476-7. Epub 2015 Mar 1.

6.

Biological sex themed section: incorporating the female dimension into cardiovascular pharmacology.

McDermott BJ, Gray GA.

Br J Pharmacol. 2014 Feb;171(3):537-40. doi: 10.1111/bph.12564. No abstract available.

7.

Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy.

Zhao Y, McLaughlin D, Robinson E, Harvey AP, Hookham MB, Shah AM, McDermott BJ, Grieve DJ.

Cancer Res. 2010 Nov 15;70(22):9287-97. doi: 10.1158/0008-5472.CAN-10-2664. Epub 2010 Sep 30.

8.

Adrenomedullin gene delivery is cardio-protective in a model of chronic nitric oxide deficiency combining pressure overload, oxidative stress and cardiomyocyte hypertrophy.

Bell D, Campbell M, Wang X, Earle JA, Cosby SL, McDermott BJ.

Cell Physiol Biochem. 2010;26(3):383-94. doi: 10.1159/000320562. Epub 2010 Aug 24.

9.

Inward rectifier potassium channels in the HL-1 cardiomyocyte-derived cell line.

Goldoni D, Zhao Y, Green BD, McDermott BJ, Collins A.

J Cell Physiol. 2010 Nov;225(3):751-6. doi: 10.1002/jcp.22278.

PMID:
20568224
10.

Effects of an endothelin receptor antagonist on a model of hypertensive retinopathy.

McDonald L, Lee GR, Degooyer TE, McDonald D, Canning P, Kelso EJ, McDermott BJ, Stitt AW.

Ophthalmic Res. 2010;43(2):99-107. doi: 10.1159/000247594. Epub 2009 Oct 15.

11.

SRIF receptor subtype expression and involvement in positive and negative contractile effects of somatostatin-14 (SRIF-14) in ventricular cardiomyocytes.

Bell D, Zhao Y, McMaster B, McHenry EM, Wang X, Kelso EJ, McDermott BJ.

Cell Physiol Biochem. 2008;22(5-6):653-64. doi: 10.1159/000185549. Epub 2008 Dec 9.

12.

Expression of the counter-regulatory peptide intermedin is augmented in the presence of oxidative stress in hypertrophied cardiomyocytes.

Bell D, Zhao Y, McCoy FP, Devine A, McDermott BJ.

Cell Physiol Biochem. 2008;21(5-6):409-20. doi: 10.1159/000129633. Epub 2008 Apr 24.

13.

Influence of atenolol and nifedipine on nitric-oxide deficient cardiomyocyte hypertrophy and expression of the cardio-endocrine peptide intermedin and its receptor components.

Bell D, Zhao YY, Devine AB, McDermott BJ.

Cell Physiol Biochem. 2008;21(1-3):203-14. doi: 10.1159/000113870. Epub 2008 Jan 17.

14.

NPY and cardiac diseases.

McDermott BJ, Bell D.

Curr Top Med Chem. 2007;7(17):1692-703. Review.

PMID:
17979778
15.

Intermedin (adrenomedullin-2): a novel counter-regulatory peptide in the cardiovascular and renal systems.

Bell D, McDermott BJ.

Br J Pharmacol. 2008 Mar;153 Suppl 1:S247-62. Epub 2007 Oct 29. Review.

17.

Protection of cardiomyocyte function by propofol during simulated ischemia is associated with a direct action to reduce pro-oxidant activity.

McDermott BJ, McWilliams S, Smyth K, Kelso EJ, Spiers JP, Zhao Y, Bell D, Mirakhur RK.

J Mol Cell Cardiol. 2007 Mar;42(3):600-8. Epub 2007 Feb 27.

PMID:
17328910
18.

Modulation of contractile function through neuropeptide Y receptors during development of cardiomyocyte hypertrophy.

Allen AR, Kelso EJ, Bell D, Zhao Y, Dickson P, McDermott BJ.

J Pharmacol Exp Ther. 2006 Dec;319(3):1286-96. Epub 2006 Sep 14.

PMID:
16973886
19.
20.

Differential expression of components of the cardiomyocyte adrenomedullin/intermedin receptor system following blood pressure reduction in nitric oxide-deficient hypertension.

Zhao Y, Bell D, Smith LR, Zhao L, Devine AB, McHenry EM, Nicholls DP, McDermott BJ.

J Pharmacol Exp Ther. 2006 Mar;316(3):1269-81. Epub 2005 Dec 2.

PMID:
16326922
21.

Alterations in vascular matrix metalloproteinase due to ageing and chronic hypertension: effects of endothelin receptor blockade.

Spiers JP, Kelso EJ, Siah WF, Edge G, Song G, McDermott BJ, Hennessy M.

J Hypertens. 2005 Sep;23(9):1717-24.

PMID:
16093917
22.

Upregulation of adrenomedullin and its receptor components during cardiomyocyte hypertrophy induced by chronic inhibition of nitric oxide synthesis in rats.

Bell D, Zhao YY, Kelso EJ, McHenry EM, Rush LM, Lamont VM, Nicholls DP, McDermott BJ.

Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H904-14. Epub 2005 Jul 22.

23.

Effects of rosiglitazone and interactions with growth-regulating factors in ventricular cell hypertrophy.

Bell D, McDermott BJ.

Eur J Pharmacol. 2005 Jan 31;508(1-3):69-76. Epub 2005 Jan 12.

PMID:
15680255
24.

Temporal characteristics of cardiomyocyte hypertrophy in the spontaneously hypertensive rat.

Bell D, Kelso EJ, Argent CC, Lee GR, Allen AR, McDermott BJ.

Cardiovasc Pathol. 2004 Mar-Apr;13(2):71-8.

PMID:
15033155
25.

Evidence for altered ETB receptor characteristics during development and progression of ventricular cardiomyocyte hypertrophy.

Lee GR, Bell D, Kelso EJ, Argent CC, McDermott BJ.

Am J Physiol Heart Circ Physiol. 2004 Jul;287(1):H425-32. Epub 2004 Feb 26.

26.

Induction of hypertrophic responsiveness of cardiomyocytes to neuropeptide Y in response to pressure overload.

Bell D, Allen AR, Kelso EJ, Balasubramaniam A, McDermott BJ.

J Pharmacol Exp Ther. 2002 Nov;303(2):581-91.

PMID:
12388639
27.

Neuropeptide Y Y(1) receptor regulates protein turnover and constitutive gene expression in hypertrophying cardiomyocytes.

Nicholl SM, Bell D, Spiers Jp, McDermott BJ.

Eur J Pharmacol. 2002 Apr 19;441(1-2):23-34.

PMID:
12007917
28.

Myocardial expression of the endothelin system in endotoxin-treated rats.

Spiers JP, Dorman A, Allen JD, Kelso EJ, Silke B, McDermott BJ.

J Cardiovasc Pharmacol. 2001 Aug;38(2):259-67.

PMID:
11483876
29.

Use of A-192621 to provide evidence for involvement of endothelin ET(B)-receptors in endothelin-1-mediated cardiomyocyte hypertrophy.

Cullen JP, Bell D, Kelso EJ, McDermott BJ.

Eur J Pharmacol. 2001 Apr 13;417(3):157-68.

PMID:
11334846
30.

Positive and negative contractile effects of somatostatin-14 on rat ventricular cardiomyocytes.

Murray F, Bell D, Kelso EJ, Millar BC, McDermott BJ.

J Cardiovasc Pharmacol. 2001 Mar;37(3):324-32.

PMID:
11243423
31.

Endothelin(A) receptor subtype mediates endothelin-induced contractility in left ventricular cardiomyocytes isolated from rabbit myocardium.

Kelso EJ, McDermott BJ, Silke B, Spiers JP.

J Pharmacol Exp Ther. 2000 Sep;294(3):1047-52.

PMID:
10945858
32.
34.
35.
37.

Receptor-mediated effects of endothelin on the L-type Ca++ current in ventricular cardiomyocytes.

Kelso EJ, Spiers JP, McDermott BJ, Scholfield CN, Silke B.

J Pharmacol Exp Ther. 1998 Aug;286(2):662-9.

PMID:
9694918
38.

Stimulation of L-type Ca2+ current by the endothelin receptor A-selective antagonist, BQ-123 in ventricular cardiomyocytes isolated from the rabbit myocardium.

Kelso EJ, Spiers JP, McDermott BJ, Scholfield CN, Silke B.

Biochem Pharmacol. 1998 Mar 15;55(6):897-902.

PMID:
9586963
39.

Enhancement of latent inhibition in the rat by the CCK antagonist proglumide.

Gracey DJ, Bell R, King DJ, Trimble KM, McDermott BJ.

Pharmacol Biochem Behav. 1998 Apr;59(4):1053-9.

PMID:
9586867
40.

Characterisation of a cellular model of cardiomyopathy, in the rabbit, produced by chronic administration of the anthracycline, epirubicin.

Kelso EJ, Geraghty RF, McDermott BJ, Cameron CH, Nicholls DP, Silke B.

J Mol Cell Cardiol. 1997 Dec;29(12):3385-97.

PMID:
9441844
41.

Evidence for Y1 and Y2 subtypes of neuropeptide Y receptors linked to opposing postjunctional effects observed in rat cardiac myocytes.

McDermott BJ, Millar BC, Dolan FM, Bell D, Balasubramaniam A.

Eur J Pharmacol. 1997 Oct 8;336(2-3):257-65.

PMID:
9384241
43.

A low dose atenolol/bendrofluazide combination in patients with mild to moderate hypertension.

Johnston GD, Wilson R, McDermott BJ, Conroy C.

J Hum Hypertens. 1997 Nov;11(11):759-60. No abstract available.

44.
45.

Involvement of endothelin (ET)A and ETB receptors in the hypertrophic effects of ET-1 in rabbit ventricular cardiomyocytes.

Mullan DM, Bell D, Kelso EJ, McDermott BJ.

J Cardiovasc Pharmacol. 1997 Mar;29(3):350-9.

PMID:
9125673
46.

Enhanced endothelium-dependent vasodilator responses in patients with systemic vasculitis.

Bruce IN, Harris CM, Nugent A, McDermott BJ, Johnston GD, Bell AL.

Scand J Rheumatol. 1997;26(4):318-24.

PMID:
9310114
47.

Endothelin-1 mediated inhibition of the acetylcholine-activated potassium current from rabbit isolated atrial cardiomyocytes.

Spiers JP, Kelso EJ, McDermott BJ, Scholfield CN, Silke B.

Br J Pharmacol. 1996 Dec;119(7):1427-37.

48.
49.

Mechanical effects of ET-1 in cardiomyocytes isolated from normal and heart-failed rabbits.

Kelso EJ, Geraghty RF, McDermott BJ, Trimble ER, Nicholls DP, Silke B.

Mol Cell Biochem. 1996 Apr 12-26;157(1-2):149-55.

PMID:
8739241
50.

ThioTEPA pharmacokinetics during intravesical chemotherapy: the influence of dose and volume of instillate on systemic uptake and dose rate to the tumour.

Masters JR, McDermott BJ, Harland S, Bibby MC, Loadman PM.

Cancer Chemother Pharmacol. 1996;38(1):59-64.

PMID:
8603453

Supplemental Content

Loading ...
Support Center